Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Design Therapeutics, Inc.

In a report released on September 11, John Shao from TD Cowen assigned a Buy rating to The Descartes Systems Group, with a price target of $121.00....

The Descartes Systems Group (DSGX) Gets a Buy from TD Cowen

BMO Capital analyst Thanos Moschopoulos maintained a Hold rating on The Descartes Systems Group yesterday and set a price target of $82.00. The com...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DSGN	$12.36	+1.98%	433.13K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DSGN	$12.36	+2.0%	433.13K
3
4
5
6

DSGN

Get Design Therapeutics, Inc. Data in Excel

Get Design Therapeutics, Inc. Data in Excel